Milena Adamian is a Managing Partner of Azimuth Ventures, a venture fund focused on early stage healthcare-centric opportunities.
 
She is also the Founder and Executive Director of Life Sciences Angel Network (predecessor of Azimuth Ventures) focused on the early stage investing in medical devices, healthcare information technology and services as well as educational activities for entrepreneurs and investors.
 
Milena brings unique perspective of a clinician and academic researcher with genuine passion for breakthrough technologies enriched by industry knowledge, Wall Street, and venture capital experience.  In last 20 years, her career included professional appointments at Interventional Cardiology department (Lenox Hill Hospital (NYC) and Columbus Hospital (Milan, Italy), Medical Director at Boston Scientific Corporation (NYSE: BSC), Equity analyst (Medical Devices and Supplies) at Lehman Brothers and Managing Director, Easton Capital. 
 
Dr. Adamian’s past and present investments and board involvements include Xoft (now NYSE: ICAD), Cardiovascular Systems (now NYSE: CSII), Forge Medical, Precise Light Surgical, Quartzy, Comprehend Systems, ZappRX, Common Sensing, BioTrace Medical, Wellframe, Owlet Care, and Lifecode Health.
 
Milena is actively involved in a number of accelerators and angel groups across the US.
 
Milena Adamian was named to the TechWeek100 list of leaders in NYC area with significant impact in business and technology and was named among 2014 – Women of Influence Honoree 2015 by New York Business Journal.
 
Dr. Adamian is a member of the American College of Cardiology and is also an author of a number of scientific peer-reviewed papers.
 
She holds an MSc degree in Biostatistics and Clinical Research Methods from Mailman School of Public Health at Columbia University, and MD and PhD degrees in Clinical Cardiology from the Russian Academy of Medical Sciences.

Fund's investment verticals: healthcare, technology enabled service and biotechnology.